Valiant Organics to start production of OAP and Pharma Intermediates
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.
He was appointed a Board member and the Chairman in 2012.
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
The company was directed to submit a plan of compliance by July 15, 2022
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Subscribe To Our Newsletter & Stay Updated